icon-folder.gif   Conference Reports for NATAP  
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
Shorter duration and lower dose of peginterferon alfa-2a therapy results in inferior HBeAg seroconversion rates compared with the duration and dose of 48 weeks and 180 µg: NEPTUNE study
  Reported by Jules Levin
AASLD 2010 Nov 2 Boston
YF Liaw,1 Q Xie,2 KH Han,3 EJ Gane,4 T Piratvisuth,5 P McCloud,6 C Wat,7 J Jia8 1. Liver Research Unit, Chang Gung Memorial Hospital and University, Taipei, Taiwan; 2. Department of Infectious Diseases, Ruijin Hospital, Shanghai, China; 3. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea ; 4. Liver Unit, Auckland City Hospital, Auckland, New Zealand; 5. NKC Institute of Gastroenterology and Hepatology, Songklanagarind Hospital, Hat Yai, Thailand; 6. Roche Products Pty Ltd, Dee Why, Australia; 7. Roche Products Ltd, Welwyn, UK; 8. Beijing Friendship Hospital, Capital Medical University, Beijing, China